Minireviews
Copyright ©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Apr 21, 2013; 19(15): 2313-2318
Published online Apr 21, 2013. doi: 10.3748/wjg.v19.i15.2313
Table 2 Traditional polysaccharide and new conjugate anti-pneumococcal vaccines used in the prophylactic management of asplenic/hyposplenic patients
VaccineBrand nameStructureMechanismSerotypeIndication
PPV23Pneumovax®PolysaccharideT-cell independent1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33FAsplenic or hyposplenic adults Asplenic or hyposplenic children > 5 yr
PCV13Prevnar®Protein-conjugate (CRM197 protein)T-cell dependent1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23FAsplenic or hyposplenic children < 5 yr